Henric Bjarke
2021
In 2021, Henric Bjarke earned a total compensation of $1.4M as Senior Vice President and Chief Operating Officer at Inozyme Pharma, a 25% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $149,925 |
|---|---|
| Option Awards | $755,981 |
| Salary | $440,955 |
| Other | $6,798 |
| Total | $1,353,659 |
Bjarke received $756K in option awards, accounting for 56% of the total pay in 2021.
Bjarke also received $149.9K in non-equity incentive plan, $441K in salary and $6.8K in other compensation.
Rankings
In 2021, Henric Bjarke's compensation ranked 7,661st out of 12,415 executives tracked by ExecPay. In other words, Bjarke earned more than 38.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,661 out of 12,415 | 38th |
Division Manufacturing | 3,374 out of 5,505 | 39th |
Major group Chemicals And Allied Products | 1,492 out of 2,375 | 37th |
Industry group Drugs | 1,326 out of 2,096 | 37th |
Industry Pharmaceutical Preparations | 980 out of 1,546 | 37th |
Source: SEC filing on April 27, 2022.
Bjarke's colleagues
We found three more compensation records of executives who worked with Henric Bjarke at Inozyme Pharma in 2021.